HB-adMSCs ( DrugBank: HB-adMSCs )
7 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 1 |
| 4 | 原発性側索硬化症 | 1 |
| 6 | パーキンソン病 | 4 |
| 13 | 多発性硬化症／視神経脊髄炎 | 1 |
| 46 | 悪性関節リウマチ | 1 |
| 49 | 全身性エリテマトーデス | 1 |
| 113 | 筋ジストロフィー | 1 |
2. 筋萎縮性側索硬化症
臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04514952 (ClinicalTrials.gov) | October 20, 2020 | 12/8/2020 | Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis | Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Biological: HB-adMSCs | Hope Biosciences Stem Cell Research Foundation | Hope Biosciences | No longer available | N/A | N/A | All | United States |
4. 原発性側索硬化症
臨床試験数 : 7 / 薬物数 : 17 - (DrugBank : 9) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 32
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04825613 (ClinicalTrials.gov) | June 1, 2021 | 25/3/2021 | Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis | Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Primary Lateral Sclerosis | Primary Lateral Sclerosis, Adult, 1 | Biological: HB-adMSCs | Hope Biosciences Stem Cell Research Foundation | Hope Biosciences | Temporarily not available | 18 Years | N/A | Male | United States |
6. パーキンソン病
臨床試験数 : 2,298 / 薬物数 : 2,202 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04995081 (ClinicalTrials.gov) | July 16, 2021 | 16/7/2021 | Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate) (PD) | A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Allogeneic HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease | Parkinson Disease | Biological: Biological/Vaccine: Allogeneic HB-adMSCs;Other: Placebo | Hope Biosciences Stem Cell Research Foundation | Hope Biosciences | Recruiting | 45 Years | 80 Years | All | 60 | Phase 2 | United States |
| 2 | NCT04772378 (ClinicalTrials.gov) | July 14, 2021 | 23/2/2021 | Individual Patient Expanded Access IND of HB-adMSCs for the Treatment of Parkinson's Disease | Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Parkinson's Disease | Parkinson Disease | Biological: HB-adMSCs | Hope Biosciences Stem Cell Research Foundation | Hope Biosciences | No longer available | 18 Years | N/A | Male | United States | ||
| 3 | NCT04928287 (ClinicalTrials.gov) | June 28, 2021 | 26/5/2021 | Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) | A Randomized, Double-Blind, Single Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Parkinson's Disease | Parkinson Disease | Biological: HB-adMSCs;Other: Placebo | Hope Biosciences Stem Cell Research Foundation | Hope Biosciences | Active, not recruiting | 18 Years | 75 Years | All | 24 | Phase 2 | United States |
| 4 | NCT04064983 (ClinicalTrials.gov) | September 14, 2019 | 19/8/2019 | Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease | Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells (HB-adMSCs) for Parkinson's Disease | Parkinson Disease | Biological: HB-adMSCs | Hope Biosciences | NULL | No longer available | 18 Years | N/A | All | United States |
13. 多発性硬化症／視神経脊髄炎
臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05116540 (ClinicalTrials.gov) | November 24, 2021 | 27/10/2021 | Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis | A Randomized, Double-Blind, Single-Center, Phase 2, Efficacy and Safety Study of Autologous HB-adMSCs vs Placebo for the Treatment of Patients With Multiple Sclerosis | Multiple Sclerosis | Biological: HB-adMSCs;Drug: Placebo | Hope Biosciences Stem Cell Research Foundation | NULL | Recruiting | 18 Years | 75 Years | All | 24 | Phase 2 | United States |
46. 悪性関節リウマチ
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03691909 (ClinicalTrials.gov) | September 25, 2018 | 27/9/2018 | A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis | A Phase 1/2a Clinical Trial to Assess Safety of a Single IV Infusion of Autologous Adipose-derived Mesenchymal Stem Cells in Adults With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: HB-adMSCs | Hope Biosciences | NULL | Completed | 18 Years | 65 Years | All | 15 | Phase 1/Phase 2 | United States |
49. 全身性エリテマトーデス
臨床試験数 : 946 / 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04907175 (ClinicalTrials.gov) | July 23, 2021 | 26/5/2021 | Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE) | Individual Patient Expanded Access IND to Evaluate the Safety and Efficacy of HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE) | System; Lupus Erythematosus | Biological: HB-adMSCs | Hope Biosciences Stem Cell Research Foundation | Hope Biosciences | Temporarily not available | 18 Years | 75 Years | Female | United States |
113. 筋ジストロフィー
臨床試験数 : 622 / 薬物数 : 485 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05154851 (ClinicalTrials.gov) | October 1, 2020 | 9/12/2021 | Individual Patient Expanded Access IND for the Treatment of Spinal Cord Injury, and Congenital Muscular Dystrophy. | Individual Patient Expanded Access IND for the Treatment of Spinal Cord Injury, and Congenital Muscular Dystrophy. | Spinal Cord Injuries;Congenital Muscular Dystrophy Due to Lamin A/C Mutation | Biological: HB-adMSCs | Hope Biosciences Stem Cell Research Foundation | NULL | No longer available | N/A | N/A | Male | United States |